Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Xoma and Servier’s mAb Fails to Reduce HbA1C Levels in Phase IIb Type 2 Diabetes Study

Xoma 052 does impact on CRP and HDL, which is promising for planned CVD and Behcet’s uveitis programs, firms claim.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »